Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patients with MDD may benefit from stress management and resiliency training

Key clinical point: A novel resiliency intervention was found to be beneficial in improving resiliency, perceived stress, and depression in patients with major depressive disorder (MDD).

Major finding: In all, 74% of the patients completed the program. A significant improvement was seen in resiliency (mean Connor Davidson Resilience Scale score, 61.1; P = .03), perceived stress (mean Perceived Stress Scale score, 19.4; P = .002), and depressive symptoms (mean scores for 17-item Hamilton Depression Rating Scale, 9.1 and 9-item Patient Health Questionnaire, 7.61; both P less than .001).

Study details: An open-label study assessed 23 patients with MDD (mean age, 46.13 years) who received adjunctive Stress Management and Resiliency Training for 8 weeks.

Disclosures: No funding information was identified. Dr. Matthew M. Clark reported receiving consultancy fees from Roche Diabetes Care GmbH. Dr. Amit Sood is the owner of Global Center for Resiliency and Wellbeing and the GRIT Institute. Dr. Mark A. Frye reported ties with multiple pharmaceutical companies and research organizations. Dr. Seshadri, Dr. Kung, Dr. Fuller-Tyszkiewicz, Dr. Tye, Dr. McGillivray, Ms. Dammen, and Mr. Rico reported no conflicts of interest.


Seshadri A et al. Prim Care Companion CNS Disord. 2020 Apr 30. doi: 10.4088/PCC.19m02556.